• Explore /
  • Poster
  • / Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab.

Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab.

Abstract Poster

Authors

Bora Lim

Bora Lim

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Bora Lim , Rashmi Krishna Murthy , Summer Jackson , Jie S. Willey , Jangsoon Lee , Ricardo H. Alvarez , Carlos Hernando Barcenas , Meghan Sri Karuturi , Nuhad K. Ibrahim , Daniel J. Booser , Stacy L. Moulder , Sharon Hermes Giordano , Abenaa M. Brewster , Ronald Stewart Walters , Powel Brown , Debu Tripathy , Vicente Valero , Naoto T. Ueno

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—HER2/ER

Track

Breast Cancer

Sub Track

HER2+

Clinical Trial Registration Number

NCT01434303

Citation

J Clin Oncol 34, 2016 (suppl; abstr 609)

DOI

10.1200/JCO.2016.34.15_suppl.609

Abstract #

609

Poster Bd #

97

Abstract Disclosures

Similar Posters

First Author: Laura Spring

First Author: S. E. Nagai

First Author: Nicholas Patrick McAndrew

First Author: Haeseong Park